Ori Capital

Ori Capital company information, Employees & Contact Information

Explore related pages

Related company profiles:

Founded in 2015, ORI Capital combines deep sector expertise with proprietary AI-driven analysis to identify, support, and scale startups addressing unmet medical needs. From early clinical development to exit, we partner with founders who are building the future of healthcare. Our AI platform supports decision-making across the full investment lifecycle -from fundraising and market validation, to talent and strategic exits. This enables a systematic, data-driven approach to value creation at every stage. We invest with purpose: to accelerate innovation that matters, and to back bold science with real-world impact. Follow us for insights on biotech innovation, venture investing, and portfolio milestones.

Company Details

Employees
27
Founded
-
Address
Room 4727-34, 47/f Sun Hung Kai Center, 30 Harbour Road, Wanchai, Hong Kong, Hong Kong,hong Kong 000000,hong Kong
Industry
Venture Capital And Private Equity Principals
NAICS
Miscellaneous Intermediation
Keywords
New York.
HQ
Hong Kong, Hong Kong
Looking for a particular Ori Capital employee's phone or email?

Ori Capital Questions

News

Old Republic International (ORI): Margin Decline Challenges Bullish Narratives Despite Discounted Valuation - Sahm

Old Republic International (ORI): Margin Decline Challenges Bullish Narratives Despite Discounted Valuation Sahm

ORI Q3 Deep Dive: Specialty Insurance Expansion Drives Growth, Market Eyes Capital Deployment - Yahoo Finance

ORI Q3 Deep Dive: Specialty Insurance Expansion Drives Growth, Market Eyes Capital Deployment Yahoo Finance

Hong Kong healthcare investor looks for biotech’s ‘DeepSeek moment’ in China - South China Morning Post

Hong Kong healthcare investor looks for biotech’s ‘DeepSeek moment’ in China South China Morning Post

China's biotech having its 'DeepSeek' moment amid big pharma M&A spree: ORI Capital founder - DealStreetAsia

China's biotech having its 'DeepSeek' moment amid big pharma M&A spree: ORI Capital founder DealStreetAsia

ORI Capital Raises $260 Million for Second Life Sciences Fund - Business Wire

ORI Capital Raises $260 Million for Second Life Sciences Fund Business Wire

HK VC firm raises $350m for Chinese healthcare startups - Tech in Asia

HK VC firm raises $350m for Chinese healthcare startups Tech in Asia

Fresh off CG Oncology exit, ORI Capital raises $260M second fund - FirstWord Pharma

Fresh off CG Oncology exit, ORI Capital raises $260M second fund FirstWord Pharma

Aramco's Wa'ed Ventures invests in AI cloud provider Ori - Data Center Dynamics

Aramco's Wa'ed Ventures invests in AI cloud provider Ori Data Center Dynamics

'Golden era of innovation': ORI Capital raises $260M fund for early-stage biotechs - Fierce Biotech

'Golden era of innovation': ORI Capital raises $260M fund for early-stage biotechs Fierce Biotech

ORI Capital, the venture firm behind CG’s big IPO, raises new biotech fund - BioPharma Dive

ORI Capital, the venture firm behind CG’s big IPO, raises new biotech fund BioPharma Dive

Tradition meets AI in Nishijinori weaving style from Japan’s ancient capital - The Seattle Times

Tradition meets AI in Nishijinori weaving style from Japan’s ancient capital The Seattle Times

ORI Capital Secures $260 Million for Second Life Sciences Fund - The Healthcare Technology Report.

ORI Capital Secures $260 Million for Second Life Sciences Fund The Healthcare Technology Report.

ORI Capital Collects $260 Million for Second Life-Sciences Venture Fund - The Wall Street Journal

ORI Capital Collects $260 Million for Second Life-Sciences Venture Fund The Wall Street Journal

Hepalink helps out ORI fund with $40m - - Global Venturing

Hepalink helps out ORI fund with $40m - Global Venturing

Exclusive: SR One raises $200M+ for third fund, still with GSK support - Endpoints News

Exclusive: SR One raises $200M+ for third fund, still with GSK support Endpoints News

AffyImmune hires former venture capital director as new leader, after first CEO departed in 4 months - Worcester Business Journal

AffyImmune hires former venture capital director as new leader, after first CEO departed in 4 months Worcester Business Journal

Avenzo, BioAge-backer Sands Capital raises new $555M life sciences fund - Fierce Biotech

Avenzo, BioAge-backer Sands Capital raises new $555M life sciences fund Fierce Biotech

If she did not have cancer, she vowed to help others who did - South China Morning Post

If she did not have cancer, she vowed to help others who did South China Morning Post

J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund - Fierce Biotech

J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund Fierce Biotech

TPG tops up funds to $580M for investments across the life sciences spectrum - Fierce Biotech

TPG tops up funds to $580M for investments across the life sciences spectrum Fierce Biotech

Regeneron Launches $500M Venture Capital Fund Skewed Toward Biotech - BioSpace

Regeneron Launches $500M Venture Capital Fund Skewed Toward Biotech BioSpace

The challenge of raising a sophomore fund - Venture Capital Journal

The challenge of raising a sophomore fund Venture Capital Journal

ALB Conversations: Edward Tung, Head of Legal and Compliance, ORI Capital - | Asian Legal Business

ALB Conversations: Edward Tung, Head of Legal and Compliance, ORI Capital | Asian Legal Business

Ori Biotech cell and gene therapy manufacturing - Amadeus Capital Partners

Ori Biotech cell and gene therapy manufacturing Amadeus Capital Partners

AffyImmune Appoints Dr. Daniel Janse as Chief Executive Officer - Business Wire

AffyImmune Appoints Dr. Daniel Janse as Chief Executive Officer Business Wire

With ties to Arie Belldegrun's Bellco, credit firm Symbiotic Capital unveils with $600M - Fierce Biotech

With ties to Arie Belldegrun's Bellco, credit firm Symbiotic Capital unveils with $600M Fierce Biotech

Venture Firms Are Using AI to Identify and Close Deals - The Wall Street Journal

Venture Firms Are Using AI to Identify and Close Deals The Wall Street Journal

Creating a new dimension: Biotech VC merging tech and life sciences unveils with $350M - Fierce Biotech

Creating a new dimension: Biotech VC merging tech and life sciences unveils with $350M Fierce Biotech

Ori Biotech reaps $100M in series B round to help launch innovative cell manufacturing tech - Fierce Pharma

Ori Biotech reaps $100M in series B round to help launch innovative cell manufacturing tech Fierce Pharma

UBS Hands Over $650 Million to Life Sciences Impact Investment Fund - BioSpace

UBS Hands Over $650 Million to Life Sciences Impact Investment Fund BioSpace

Longevity investors look to add $200M to the table with new growth fund - Endpoints News

Longevity investors look to add $200M to the table with new growth fund Endpoints News

ORI Hits 52-Week High, Trades at a Discount: How to Play the Stock - TradingView

ORI Hits 52-Week High, Trades at a Discount: How to Play the Stock TradingView

Joe Jimenez and Mark Fishman target $400M for third fund after leaving Novartis - Endpoints News

Joe Jimenez and Mark Fishman target $400M for third fund after leaving Novartis Endpoints News

Chinese Media Giant ORI to Invest USD 533M in Saudi’s Cultural Sector - waya.media

Chinese Media Giant ORI to Invest USD 533M in Saudi’s Cultural Sector waya.media

AI compute provider Ori raises $140m to roll out access to Nvidia superchips - Sifted

AI compute provider Ori raises $140m to roll out access to Nvidia superchips Sifted

China’s Ori Group establishes Saudi regional HQ with $540m investment - Arab News

China’s Ori Group establishes Saudi regional HQ with $540m investment Arab News

CG brings back the crossover round, reeling in $105M to fund phase 3 bladder cancer trial - Fierce Biotech

CG brings back the crossover round, reeling in $105M to fund phase 3 bladder cancer trial Fierce Biotech

Rivus raises $132M series B as obesity, NASH prospects for metabolic drug heat up - Fierce Biotech

Rivus raises $132M series B as obesity, NASH prospects for metabolic drug heat up Fierce Biotech

CG Oncology aims for $181M listing in first biotech IPO of 2024 - Endpoints News

CG Oncology aims for $181M listing in first biotech IPO of 2024 Endpoints News

AffyImmune attracts $30M with its CAR-T strategy for beleaguered solid tumor cancers - Fierce Biotech

AffyImmune attracts $30M with its CAR-T strategy for beleaguered solid tumor cancers Fierce Biotech

AffyImmune Therapeutics Appoints Matt Britz as Chief Executive Officer and Pete Gelinas as SVP of CMC - BioSpace

AffyImmune Therapeutics Appoints Matt Britz as Chief Executive Officer and Pete Gelinas as SVP of CMC BioSpace

Saudi Aramco’s Wa’ed Ventures backs Ori to drive edge AI expansion in Middle East - Edge Industry Review

Saudi Aramco’s Wa’ed Ventures backs Ori to drive edge AI expansion in Middle East Edge Industry Review

Tiny player picks up $30M to go after CAR-T’s biggest challenges - Endpoints News

Tiny player picks up $30M to go after CAR-T’s biggest challenges Endpoints News

Pierre Socha on the Future of Regenerative Medicine - Amadeus Capital Partners

Pierre Socha on the Future of Regenerative Medicine Amadeus Capital Partners

CG Oncology Raises $120M for Research - Orange County Business Journal

CG Oncology Raises $120M for Research Orange County Business Journal

Big Pharmas Amgen, BMS shield BigHat from stormy market with $75M funding - Fierce Biotech

Big Pharmas Amgen, BMS shield BigHat from stormy market with $75M funding Fierce Biotech

How This 31-Year-Old Raised $120 Million in a Frozen Biotech Market - businessinsider.com

How This 31-Year-Old Raised $120 Million in a Frozen Biotech Market businessinsider.com

AffyImmune’s layoffs; Henlius makes a biosimilar deal with Dr. Reddy’s - Endpoints News

AffyImmune’s layoffs; Henlius makes a biosimilar deal with Dr. Reddy’s Endpoints News

Apnimed closes $62.5M series C after working tirelessly on lead sleep disorder drug - Fierce Biotech

Apnimed closes $62.5M series C after working tirelessly on lead sleep disorder drug Fierce Biotech

Biopharma charts progress in translating CAR-T cell therapies to solid cancers - Fierce Biotech

Biopharma charts progress in translating CAR-T cell therapies to solid cancers Fierce Biotech

Ori secures Investment from Wa’ed Ventures - UK Tech Investment News

Ori secures Investment from Wa’ed Ventures UK Tech Investment News

China’s Biotech Boom Signals Global Ambition - china-britain business focus

China’s Biotech Boom Signals Global Ambition china-britain business focus

Faropoint Completes $105 Million Off-Market Acquisition of 16-Building Portfolio in Jacksonville, FL and Memphis, TN - Business Wire

Faropoint Completes $105 Million Off-Market Acquisition of 16-Building Portfolio in Jacksonville, FL and Memphis, TN Business Wire

The Fortune Global Technology Forum, Day One: CEO Daily - Fortune

The Fortune Global Technology Forum, Day One: CEO Daily Fortune

What is the future of digital art investment? - Campden FB

What is the future of digital art investment? Campden FB

Alphabet and other giants are betting that the future of real estate is robotic - Fast Company

Alphabet and other giants are betting that the future of real estate is robotic Fast Company

12 UK soonicorns to watch - Sifted

12 UK soonicorns to watch Sifted

Aramco’s VC arm invests in AI cloud startup Ori - Tech in Asia

Aramco’s VC arm invests in AI cloud startup Ori Tech in Asia

GSK Hands Off Rare Disease Gene Therapy Portfolio to Orchard Therapeutics - Genetic Engineering and Biotechnology News

GSK Hands Off Rare Disease Gene Therapy Portfolio to Orchard Therapeutics Genetic Engineering and Biotechnology News

Antelope Systems' CEO Ori Hazan Quits to Launch New Venture - Finance Magnates

Antelope Systems' CEO Ori Hazan Quits to Launch New Venture Finance Magnates

Cold Genesys’ Arthur Kuan Is Helping To Reinvent The Way We Approach Cancer | Forbes - Forbes Africa

Cold Genesys’ Arthur Kuan Is Helping To Reinvent The Way We Approach Cancer | Forbes Forbes Africa

Hedge Fund and Insider Trading News: Bridgewater Associates, Winton Capital, Heron Therapeutics Inc (HRTX), Accuray Incorporated (ARAY), and More - Insider Monkey

Hedge Fund and Insider Trading News: Bridgewater Associates, Winton Capital, Heron Therapeutics Inc (HRTX), Accuray Incorporated (ARAY), and More Insider Monkey

ARTHUR KUAN, 29 - PressReader

ARTHUR KUAN, 29 PressReader

Top Ori Capital Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant